The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly

J Clin Endocrinol Metab. 1987 Jan;64(1):37-42. doi: 10.1210/jcem-64-1-37.

Abstract

SMS 201-995 (SMS) is a long-acting analog of somatostatin. We studied the effect of SMS (50-100 micrograms, sc, every 8 h) on serum GH in five patients with acromegaly. Serum GH decreased significantly in four of the five patients 4 h after SMS treatment. In two of the four patients, this reduction was not sustained for 7 h, but sustained reduction to normal GH concentrations did occur in the two patients who had basal serum GH levels below 15 ng/ml. In the two patients whose responses were not sustained for 7 h, a higher dose of SMS did not cause sustained reduction in GH. SMS was well tolerated, except for one episode of elevated serum aminotransferase levels. These results indicate that SMS-induced reductions in serum GH in patients with acromegaly are often not sustained despite SMS administration every 8 h and indicate that the insufficient duration of effect may limit its therapeutic efficacy.

MeSH terms

  • Acromegaly / blood
  • Acromegaly / drug therapy*
  • Adult
  • Circadian Rhythm
  • Dose-Response Relationship, Drug
  • Female
  • Growth Hormone / blood*
  • Humans
  • Male
  • Middle Aged
  • Octreotide
  • Somatostatin / analogs & derivatives*
  • Somatostatin / blood
  • Somatostatin / therapeutic use
  • Time Factors

Substances

  • Somatostatin
  • Growth Hormone
  • Octreotide